Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire) - Aug 13, 2024 - "Recent Business Highlights and Select Anticipated Milestones - Luveltamab Tazevibulin (luvelta), FRα-Targeting ADC Franchise: (i) Sutro will present updated data from the Phase 1b study of luvelta in combination with bevacizumab for patients with ovarian cancer in a poster presentation at the...ESMO Congress 2024...; (ii) REFRαME-P1, a registration-enabling trial for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) AML, is expected to be initiated in the second half of 2024; (iii) A Phase 2 expansion study in combination with bevacizumab is ongoing, with data expected in the first half of 2025; (iv) A Phase 2 trial for the treatment of NSCLC is expected to initiate in the second half of 2024, with initial data expected in the first half of 2025."
New P2 trial • New trial • P1 data • P2 data • Acute Myelogenous Leukemia • Non Small Cell Lung Cancer • Ovarian Cancer
|